Unlocking the promise of oncolytic virotherapy in glioma: Combination with chemotherapy to enhance efficacy

Drew A. Spencer, Jacob S. Young, Deepak Kanojia, Julius W. Kim, Sean P. Polster, Jason P. Murphy, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Malignant glioma is a relentless burden to both patients and clinicians, and calls for innovation to overcome the limitations in current management. Glioma therapy using viruses has been investigated to accentuate the nature of a virus, killing a host tumor cell during its replication. As virus mediated approaches progress with promising therapeutic advantages, combination therapy with chemotherapy and oncolytic viruses has emerged as a more synergistic and possibly efficacious therapy. Here, we will review malignant glioma as well as prior experience with oncolytic viruses, chemotherapy and combination of the two, examining how the combination can be optimized in the future.

Original languageEnglish (US)
Pages (from-to)453-468
Number of pages16
JournalTherapeutic Delivery
Volume6
Issue number4
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Unlocking the promise of oncolytic virotherapy in glioma: Combination with chemotherapy to enhance efficacy'. Together they form a unique fingerprint.

  • Cite this